T2	total-participants 479 482	340
T3	eligibility 483 577	patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery
T4	outcome 1541 1549	pCR rate
T5	outcome 1436 1485	toxicity, no cardiac toxicity, and no toxic death
T6	outcome 1319 1327	pCR rate
T7	iv-bin-percent 1336 1339	26%
T8	cv-bin-percent 1393 1396	19%
T9	outcome 1137 1140	pCR
T10	iv-bin-percent 1204 1208	11.5
T11	cv-bin-percent 1213 1216	13%
T12	outcome 1109 1135	In the HER2 negative group
T13	outcome 1291 1317	In the HER2 positive group
T14	total-participants 787 790	220
T15	total-participants 967 970	120
T17	control 890 913	no additional treatment
T1	intervention 43 144	sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab
T16	eligibility 759 781	HER2-negative patients
T18	outcome 1593 1602	pCR rates
